VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Large Decrease in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 19,972 shares, a decrease of 40.1% from the May 31st total of 33,344 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily volume of 58,969 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

VivoSim Labs Stock Performance

VIVS traded down $0.08 during trading on Thursday, reaching $0.98. The company’s stock had a trading volume of 128,101 shares, compared to its average volume of 850,552. The company’s fifty day moving average price is $1.27 and its 200-day moving average price is $1.68. VivoSim Labs has a 52-week low of $0.94 and a 52-week high of $5.30. The company has a market capitalization of $2.56 million, a price-to-earnings ratio of -0.31 and a beta of 1.38.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is owned by institutional investors and hedge funds.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.